Bio-Rad Laboratories Inc (BIO) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.

Total Revenue Chart for Bio-Rad Laboratories Inc

Bio-Rad Laboratories Inc (BIO) revenue for FY2025 was USD 2.6B, a 0.7% change from FY2024. Bio-Rad Laboratories Inc's revenue grew from USD 102.3M in 1985 to USD 2.6B in 2025 (2425.1% over 40 years). Earnings per share grew from USD 1.29 in 2000 to USD 27.85 in 2025 (2051.3%). Revenue compound annual growth rate: 5-year CAGR of 0.3%, 10-year CAGR of 2.5%, 20-year CAGR of 4.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$9.87B
Implied Share Price
$454.85
Enterprise Value
$9.81B
Revenue (TTM)
$2.59B
EBITDA
$441.00M
Profit Margin
8.59%
Trailing P/E
48.15
Forward P/E
41.32
Price/Book (MRQ)
1.41
Price/Sales (TTM)
3.81
EV/EBITDA
17.28
EV/Revenue
3.79
Dividend Yield
—
Book Value
$268.30
Free Cash Flow (FY2025)
$374.60M
Free Cash Flow Yield
3.80%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.